Sana Biotechnology, Inc.
General ticker "SANA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $867.8M (TTM average)
Sana Biotechnology, Inc. follows the US Stock Market performance with the rate: 26.6%.
Estimated limits based on current volatility of 3.1%: low 3.12$, high 3.33$
Factors to consider:
- Total employees count: 194 (-40.9%) as of 2024
- Top business risk factors: Operational and conduct risks, Supply chain disruptions, Labor/talent shortage/retention, Stem cell supply risks, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.83$, 7.55$]
- 2026-12-31 to 2027-12-31 estimated range: [2.64$, 7.00$]
Financial Metrics affecting the SANA estimates:
- Positive: with PPE of -6.6 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: 19.24 < Shareholder equity ratio, % of 38.59 <= 42.59
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term SANA quotes
Long-term SANA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $293.14MM | $272.72MM | $250.32MM |
| Operating Income | $-293.14MM | $-272.72MM | $-250.32MM |
| Non-Operating Income | $9.89MM | $5.96MM | $6.15MM |
| R&D Expense | $261.81MM | $215.67MM | $131.98MM |
| Income(Loss) | $-283.25MM | $-266.76MM | $-244.17MM |
| Net Income(Loss)* | $-283.25MM | $-266.76MM | $-244.17MM |
| Stockholders Equity | $287.51MM | $250.50MM | $160.88MM |
| Assets | $565.30MM | $501.02MM | $416.89MM |
| Operating Cash Flow | $-253.58MM | $-223.15MM | $-143.83MM |
| Capital expenditure | $20.03MM | $33.43MM | $0.94MM |
| Investing Cash Flow | $172.01MM | $17.45MM | $-40.24MM |
| Financing Cash Flow | $31.65MM | $199.75MM | $128.73MM |
| Earnings Per Share** | $-1.46 | $-1.16 | $-0.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.